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Abstract
 
CD43 is a large heavily glycosylated protein highly expressed on T cells and actively excluded
from the immunological synapse through interactions with ezrin-radixin-moesin proteins. Due
to its size and charge, it has been proposed that the CD43 ectodomain acts as a physical barrier
to T cell–APC interactions. We have addressed this hypothesis by studying the effect of recon-
stituting CD43 mutants into the hyperproliferative CD43
 
 
 
/
 
 
 
 T cells. Reintroduction of full-
length CD43 reversed the CD43
 
 
 
/
 
 
 
 T cell hyperproliferation. Interestingly, despite the lack of
exclusion from the interaction site, a mutant containing the CD43 ectodomain on a glyco-
sylphosphatidylinositol linkage was ineffective. Additionally, T cell–APC conjugate formation
was not affected by this ectodomain-only construct. In contrast, CD43
 
 
 
/
 
 
 
 T cell hyperprolifer-
ation was reversed by an intracellular-only CD43 fused to the small ectodomain of hCD16.
Mutation of this intracellular-only CD43 such that it could not move from the T cell–APC
contact site had no further affect on proliferation than the moveable CD43 but did dramatically
reduce interleukin-2 production. Thus, the exclusion of the CD43 intracellular region from
the immunological synapse is required for CD43 regulation of interleukin-2 production, but
the presence of the cytoplasmic tail, independent of its location, is sufficient to reverse CD43
 
 
 
/
 
 
 
T cell hyperproliferation.
Key words: CD43 • CD25 • proliferation • adhesion • SMAC
 
Introduction
 
CD43, also known as leukosialin or sialophorin, is a heavily
glycosylated transmembrane protein expressed on most
hemopoietic cells except erythrocytes (1–3). The extracel-
lular domain (ECD) of CD43 has an elongated, unfolded
structure that is predicted to extend 45 nm from the phos-
pholipid bilayer, making it the largest glycoprotein on the
cell surface (4), and CD43 has been estimated to cover up
to 28% of the surface area on rat thymocytes (5). The extra-
cellular domain of CD43 contains 
 
 
 
80 serine or threonine
residues, most of which are O-glycosylated, bearing numer-
ous sialic acids residues (4). The cytoplasmic region of murine
CD43 consisting of 124 amino acids is highly homologous
(70% identity) to human CD43 (6).
The function of CD43 remains elusive (7). Targeted dis-
ruption of CD43 in mice and cell lines leads to increased T
cell proliferation and adhesion in vitro (8, 9) and increased
immune responses in vivo (10). However, cross-linking
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Abbreviations used in this paper: 
 
DO.CD43
 
 
 
/
 
 
 
, DO.11.10.CD43
 
 
 
/
 
 
 
;
CD16-7, the ectodomain of human CD16 fused to the transmembrane of
human CD7; CD16-7-43, the CD16-7 construct fused to the ICD of
murine CD43; CD16-7–NGG, CD16-7-43 with the ERM binding
KRR motif mutated to the ERM nonbinding NGG motif; CD43FL,
full-length murine CD43; CD43GPI, the ectodomain of murine CD43
fused to a GPI anchor; CD43–NGG, the full-length mCD43 with the
ERM binding KRR motif mutated to the ERM non-binding NGG
motif; CFSE, carboxyfluorescein diacetate succinimidyl ester 5-(and 6-);
C-SMAC, central supramolecular activation cluster; ECD, extracellular
domain; ERM, ezrin-radixin-moesin; GPI, glycosylphosphatidylinositol;
ICD, intracellular domain. 
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CD43 concurrently with TCR ligation induces a dramatic
costimulatory response that is independent of CD28 (11).
Recently, Onami et al. have suggested that for in vivo
CD8 responses, CD43 is costimulatory early in the re-
sponse but a negative effector molecule later (12).
The prevailing hypothesis in the literature is that CD43
has a negative function due to an effect on cell–cell repul-
sion mediated by its extensive sialylated O-glycans (the
“barrier hypothesis”). This hypothesis has been seemingly
supported by demonstration that TCR signaling induces
selective exclusion of CD43 from the T cell antigen–pre-
senting cell contact site via its interaction with the family of
cytoskeletal adaptor proteins, ezrin-radixin-moesin (ERM;
13–16). Interestingly, inhibition of CD43 movement leads
to decreased IL-2 and IFN-
 
 
 
 production (14, 15). To-
gether, these data suggest that CD43 could represent a
novel type of cell surface regulatory protein that dampens
T cell responses by its physical presence and is specifically
removed upon T cell activation.
To directly test whether it is the presence of the CD43–
ECD in the T cell–APC interaction site that dampens T
cell responses, structure/function studies were done. Addi-
tionally, ECD-only and intracellular domain (ICD)-only
constructs as well as ICD-only constructs mutated at the
ERM-binding site were tested. The CD43–ECD fusion
protein failed to be excluded from the immunological syn-
apse, yet did not interfere with T cell–APC conjugate for-
mation or reduce CD43
 
 
 
/
 
 
 
 T cell hyperproliferation.
However, the ICD of CD43 was sufficient to effectively
reverse CD43
 
 
 
/
 
 
 
 T cell hyperactivation. Interestingly, mu-
tation of the intracellular region construct so that it could
not bind ERM proteins or move from the site of TCR sig-
naling further decreased IL-2 production. Thus, our data
definitively demonstrates that it is the ICD of CD43, not
the ectodomain, which confers negative regulation of T
cell activation.
 
Materials and Methods
 
Mice.
 
CD43
 
 
 
/
 
 
 
 mice (provided by Dr. Blair Ardman, Tufts
University, Medford, MA; reference 8) were backcrossed to
BALB/c (The Division of Cancer Treatment, National Cancer
Institute) six times and bred to the TCR Tg DO.11.10 as de-
scribed previously to produce the DO.CD43
 
 
 
/
 
 
 
 strain (14).
DBA/2NCr were purchased from NCI-FCRDC. All mice
housed at the University of Chicago were bred and/or main-
tained in a specific pathogen-free condition in barrier facilities.
The studies reported here conform to the principles outlined by
the Animal Welfare Act and NIH guidelines.
 
Antibodies and Other Reagents.
 
Affinity-purified anti-CD28
(PV-1; reference 17) and anti-CD3 (145–2C11; reference 18)
were prepared in our laboratory. mAbs for mouse CD43 (S7),
human CD16 (3G8), and mouse CD25 (7D4) were purchased
from BD Biosciences. Rabbit anti–PKC-
 
 
 
 (C-18) was from
Santa Cruz Biotechnology, Inc. HRP-conjugated goat anti–
mouse and goat anti–rabbit Ig were purchased from Bio-Rad
Laboratories. FITC or Texas red donkey anti–rat IgG (mouse ad-
sorbed), Texas red donkey anti–rabbit Ig (mouse absorbed), and
Texas red donkey anti–goat Ig were all from Jackson Immu-
noResearch Laboratories. The OVA
 
323–339
 
 peptide was produced
by the University of Chicago Peptide Synthesis Facility.
 
Production of Primary T Cell Lymphoblasts.
 
LN T cells from
DO.11.10 and DO.CD43
 
 
 
/
 
 
 
 mice were enriched by nonadher-
ence to nylon wool as previously described (11). The T cells (2 
 
 
 
10
 
5
 
 cells/well) were stimulated with irradiated DBA/2 spleno-
cytes (6 
 
 
 
 10
 
6
 
 cells/well) and chicken ovalbumin peptide
(OVA
 
323–339
 
) at 0.15 
 
 
 
g/ml in complete media (DME media
[Life Technologies] supplemented with 5% heat-inactivated FCS,
100 U/ml penicillin, 100 
 
 
 
g/ml streptomycin, 0.29 mM 
 
l
 
-gluta-
mine, nonessential amino acids, 10 mM Hepes, and 5 
 
 
 
 10
 
 
 
5
 
 M
 
 
 
-mercaptoethanol). After 4 d of culture, 1 ml of complete me-
dia was added to each well. T cells were harvested and live cells
recovered by Ficoll-Hypaque gradient separation 9–14 d after
initial stimulation.
 
Transduction of Retroviral Constructs into Primary T Cells.
 
The
following vectors were used: full-length murine CD43 (CD43FL);
full-length mCD43 with the ERM binding KRR motif mutated
to the ERM nonbinding NGG motif (CD43–NGG); ecto-
domain of murine CD43 fused to a GPI anchor (CD43GPI);
ectodomain of human CD16 fused to the transmembrane of
human CD7 (CD16-7); CD16-7 construct fused to the ICD of
murine CD43 (CD16-7-43); and CD16-7-43 with the ERM
binding KRR motif mutated to the ERM nonbinding NGG
motif (CD16-7–NGG). Construction of retroviral vectors and
transduction methods have been published previously in detail
(14). Briefly, Phoenix packaging cells transfected by calcium
phosphate T cells from DO.CD43
 
 
 
/
 
 
 
 mice were plated on anti-
CD3/CD28–coated plates. At 48 h after transfection, the virus
particles and Phoenix packaging were harvested and inactivated.
The Phoenix cells and their virus-containing supernatants were
recombined and overlaid onto the activated T cell cultures in the
presence of hexadimethrene bromide (Sigma-Aldrich) to enhance
the infection. The transduced T cells were used in experiments
within 7–14 d and sorted for CD43 or hCD16 expression using
the MoFlo (Cytomation). Transduced cells consistently expressed
the transgene at high levels (Fig. S1, available at http://www.
jem.org/cgi/content/full/jem.20021602/DC1), and sorting gates
were used to ensure similar levels of transgene expression in all
populations.
 
Immunofluorescence Staining and Microscopy.
 
T cell lympho-
blasts were conjugated with OVA
 
323–339
 
–pulsed A20 (2 
 
 
 
g/ml)
and stained for immunofluorescence as described in detail in Al-
lenspach et al. (14). Briefly, conjugates were washed, adhered to
poly-
 
l
 
-lysine–coated coverslips, and fixed. Fixation of the GPI-
anchored CD43 conjugates was done with 4% PFA/0.1% glutar-
aldehyde/PBS to fix lipid rafts. The samples were quenched, per-
meabilized, and blocked. The fixed cells were stained with the
primary antibodies, washed, and then stained with the fluoro-
chrome-labeled secondary antibodies. Cells were observed using
a 63
 
 
 
 Planapo objective and photographed using a Carl Zeiss
MicroImaging, Inc. Axiovert equipped with a Micromax cooled
CCD camera (Roper). Single images were processed by no-
neighbor deconvolution using SlideBook 3.0 (Intelligent Imaging
Innovations) to remove out of focus haze. For en face analysis of
the T cell–APC interface, z-series images were processed by
nearest-neighbor deconvolution and rendered in three dimension
using Slidebook.
 
Flow Cytometry and ELISA.
 
After sorting, transduced T cells
were labeled with 3.33 
 
 
 
M carboxyfluorescein diacetate succin-
imidyl ester 5-(and 6-) (CFSE; Molecular Probes), and then 10
 
5
 
T cells per well were stimulated with mitomycin C–treated anti-
gen-pulsed A20 cells (10
 
5
 
 cells/well). At day 3, the T cells were 
Tong et al. Brief Definitive Report
 
1279
 
recovered and stained with anti-CD43, and flow cytometric anal-
ysis was performed. Data were analyzed using CellQuest and
Modfit software to determine the percentage of cells in each gen-
eration. Expression of CD25 was determined at 24 h activation.
Supernatants were collected 24 h after activation and assayed for
IL-2 production by ELISA (BD Biosciences).
 
Heteroconjugate Adhesion Assay.
 
A20 B lymphoma cells were
stained according to manufacturer’s instructions with the vital
dye PKH26 (Sigma-Aldrich), a membrane marker that fluoresces
in the same wavelength as phycoerythrin. The cells were washed,
pulsed with OVA peptide as above, and resuspended to 5 
 
 
 
 10
 
5
 
cells/ml. T cells were stained according to manufacturer’s in-
structions with Calcein-AM a cytoplasmic dye (Sigma-Aldrich)
that emits in the same wavelength as fluorescein. Prior to mixing
the T cells with APCs, the cells were washed once in 5% DMEM
and resuspended to 5 
 
 
 
 10
 
5
 
 cells/ml. APCs were added at equal
volumes to the appropriate T cells. The mixture of cells was cen-
trifuged at 500 rpm for 5 min at 4
 
 
 
C and vortexed for 10 s at set-
ting 4. After agitation, the cell mixtures were incubated in a 37
 
 
 
C
water bath for the different times as indicated. The samples were
vortexed for 30 s at setting 2 for naive cells and setting 8 for pre-
viously activated cells and then immediately fixed with an equal
volume of 6% paraformaldehyde in PBS. Conjugates were mea-
sured by flow cytometry, and the percent of T cells in conjugates
was determined. Triplicate samples were used to determine SDs.
 
Online Supplemental Material.
 
Fig. S1 shows that the T cell
transduced with CD43 mutant constructs expresses equal levels
of the control and mutant proteins.  Fig. S2 shows a second T
cell–APC conjugate similar to Fig. 2 A that demonstrates that
CD43GPI is located throughout the immunological synapse in-
cluding the C-SMAC.  Online supplemental material is available
at http://www.jem.org/cgi/content/full/jem.20021602/DC1.
 
Results and Discussion
 
CD43 Negatively Regulates T Cell Proliferation and Acti-
vation in Antigen-specific Responses.
 
Mitogen or alloantigen
stimulation has been shown to induce increased prolifera-
tion of CD43-deficient T cells compared with WT T cells
(8, 9). To test whether this hyperproliferation would
also be found in an antigen-specific model, CD43
 
 
 
/
 
 
 
mice were bred to the DO11.10 TCR transgenic strain
(DO.CD43
 
 
 
/
 
 
 
). WT and DO.CD43
 
 
 
/
 
 
 
 T lympho-
blasts were labeled with CFSE dye and cocultured with
OVA
 
323–339
 
–pulsed A20 cells. We found a significant differ-
ence between DO.CD43
 
 
 
/
 
 
 
 and WT DO11.10 T cells.
The two populations divided similarly on day 2, but on
days 3 and 4 the DO.CD43
 
 
 
/
 
 
 
 T cells underwent more
cell divisions when compared with WT T cells (Fig. 1 A
and not depicted). 24 h after activation, CD25 expression
on the DO.CD43
 
 
 
/
 
 
 
 T cells was also higher than on WT
T cells (Fig. 1 B), suggesting that the signals for hyperpro-
Figure 1. CD43 negatively reg-
ulates T cell proliferation and acti-
vation but does not affect forma-
tion of T cell–APC conjugates.
(A) Rested DO.CD43 /  and
DO11.10 lymphoblast were dyed
with CFSE and stimulated with
OVA peptide (0.3  g/ml)–pulsed
A20 B cells. Daughter generations
were determined by measuring the
CFSE peaks that shift to the right
of the parental peak with Modfit
software. CD43 /  T cells divide
and undergo more divisions com-
pared with CD43 WT T cells on
day 3. (B) CD25 expression at 24 h
after stimulation with OVA pep-
tide (0.3  g/ml) pulsed A20 cells
is decreased on CD43 WT T cells.
*P   0.05; **P   0.01. Data are
from one representative experi-
ment of a total of three indepen-
dent experiments. (C and D) A
flow cytometric based assay was
used to determine adhesion be-
tween DO11.10 (circles) or
DO.CD43 /  (squares) T cells
and OVA-pulsed (filled symbols)
or unpulsed (open symbols) A20
cells. No difference was found be-
tween CD43 /  and WT murine
T cells to form conjugates with 0.3
 g/ml of OVA peptide–pulsed
APC. Naive (C) and previously
activated (D) T cells were tested.
Data are from one representative
experiment of a total of three in-
dependent experiments. 
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liferation may occur within this time period. Similar results
were found when naive T cells were used (unpublished
data). Thus, similar to mitogenic stimuli, antigen-specific
stimulation also induces hyperproliferation and activation
of CD43
 
 
 
/
 
 
 
 T cells.
 
DO.CD43
 
 
 
/
 
 
 
 T Cells Do Not Display Increased Heterocon-
jugate Adhesion.
 
A model of T cell activation based on T
cell topology and a sorting of surface molecules by size and
charge has been proposed (19, 20). In this model, CD43,
being one of the largest and most highly charged molecules
on the cell surface, would need to be removed from the in-
teraction site in order for the T cell receptor to make con-
tact with the class II molecules on the APC. Thus, it has
been suggested that CD43 may regulate cellular interac-
tions by providing a physical constraint and thereby affect
the ability of T cells to form the necessary interaction site
with APC. In agreement with this model, increased homo-
typic adhesion has been reported in cultures of cells lacking
CD43 (5, 8, 9). However, the presumed interference of
CD43 with T cell–APC heterotypic adhesion has never
been addressed directly. To determine if CD43 actually af-
fects the formation of heterotypic cellular conjugates, we
developed a flow cytometric assay to measure the number
of conjugates and the rate of their formation in vitro. Con-
trary to our expectations, we found that there is no differ-
ence between DO.CD43
 
 
 
/
 
 
 
 and WT murine T cells with
respect to the rate and degree of conjugate formation with
APC (Fig. 2). This was true whether the T cells were iso-
lated directly ex vivo or were from lymphoblast cultures.
These data suggest that the hyperproliferative response of
DO.CD43
 
 
 
/
 
 
 
 T cells is not due to a greater ability of these
T cells to form conjugates with APC.
 
The Presence of the CD43 Ectodomain in the T Cell–APC
Interaction Site Does Not Affect T Cell Activation or Adhesion.
 
For years, it has been proposed that CD43 negatively regu-
lates T cell activation by acting as a physical barrier to cel-
lular interactions and that its removal is necessary for nor-
mal T cell activation. Although we observed no difference
in conjugate formation with APC between DO.CD43
 
 
 
/
 
 
 
and WT T cells, we and others have found that TCR sig-
naling induces exclusion of CD43 from the T cell–APC
contact site (13–16). Thus, it was still possible that be-
fore removal of CD43 from the interaction site there is a
short period of steric interference. To address this question,
we produced a fusion molecule with the ectodomain of
CD43GPI and transduced DO.CD43
 
 
 
/
 
 
 
 T cells with ei-
ther CD43FL or CD43GPI as described previously (14).
CD43FL was excluded from the interaction site similar to
WT CD43 on T cells, whereas CD43GPI was not ex-
cluded (Fig. 2 A). In fact, the CD43GPI tended to move
toward the interaction site. This is most likely due to the
enrichment of GPI-linked proteins in the cholesterol-rich
lipid rafts that are known to coalesce at the interaction site
(21). To examine the location of the CD43GPI within the
immunological synapse, we performed three-dimensional
rendering of the TCR surface at the T cell–APC contact
site and determined that the CD43GPI was distributed
throughout the entire contact area. Importantly, double la-
beling with anti–PKC-
 
 
 
 shows that CD43GPI is present in
the PKC-
 
 
 
–rich central supramolecular activation cluster
(C-SMAC) region where sustained TCR–MHC interac-
tions are proposed to occur.
The production of a mutant CD43 molecule that
contains no transmembrane or cytoplasmic region, which
through its GPI linkage actually moves the ectodomain of
CD43 toward the T cell–APC contact site, allowed for a
direct test of the “barrier hypothesis.” If this hypothesis is
correct, then the CD43GPI mutant that places CD43 in
Figure 2. The ectodomain of CD43GPI is present throughout the T
cell–APC interaction site, yet has no affect on T cell–APC conjugate for-
mation. (A) DO.CD43GPI T cells (small cells on the right in each picture)
were conjugated with antigen-pulsed A20 B cells (large cells on left),
fixed, and double labeled for CD43 and PKC-  as described in Materials
and Methods. (A second example of a different CD43GPI-transduced T
cell–APC conjugate is found in Fig S2, available at http://www.jem.org/
cgi/content/full/jem.20021602/DC1). z-series images were collected,
and digital deconvolution and three-dimensional rendering of the cell–cell
interface demonstrated that although PKC-  was focused in the C-SMAC,
the CD43GPI molecule was distributed throughout the entire contact
area. (B) Using the flow cytometric based adhesion assay described in the
legend to Fig. 1, no difference in conjugate formation between CD43 / 
and CD43GPI-transduced T cells with 0.3  g/ml of OVA peptide–
pulsed A20 cells was found. 
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the T cell–APC contact site should decrease T cell func-
tion. Yet, no significant differences between the adhesive
capabilities of CD43
 
 
 
/
 
 
 
 and CD43GPI-transduced T cells
could be discerned (Fig. 2 B). Both populations formed
equal numbers of conjugates with OVA peptide–pulsed
APC at all time points examined. Thus, the theory that
CD43 must be removed from the interaction site to facili-
tate T cell–APC adhesion is not supported by our data.
Further, if the barrier hypothesis was correct, GPI-linked
CD43 should have had a greater tendency to inhibit T cell
activation than CD43FL which is actively moved to the
distal pole complex. Again, our data does not support
this hypothesis. Transduction of CD43FL into CD43
 
 
 
/
 
 
 
T cells diminished proliferation and CD25 expression,
whereas transduction of the CD43GPI molecule had no
effect on the hyperproliferation of CD43
 
 
 
/  T cells (Fig.
3). Thus, we have directly disproven the size-exclusion
barrier hypothesis.
The Cytoplasmic Tail of CD43 Is Sufficient for Diminished T
Cell Proliferation. Our results with the CD43GPI con-
struct demonstrate that the negative regulation of T cell ac-
tivation by CD43 is not due to the presence of the ECD in
the T cell–APC interaction site. Since the CD43FL was
able to reconstitute the WT phenotype, these data suggest
that the ICD is necessary for the negative regulatory func-
tion of the molecule. To test this hypothesis, an “intracel-
lular only” construct was used (14). This fusion molecule
consists of the ECD of human CD16, the transmembrane
region of human CD7, and the ICD of murine CD43
(CD16-7-43). The construct and its control, CD16-7,
were transduced into CD43 /  T cells, and the result-
ing populations were sorted and tested for proliferation
and CD25 expression (Fig. 4, A and B). The CD16-7-
43–transduced cells proliferated slower and expressed less
CD25 than the CD16-7 cells. Therefore, these data dem-
onstrate that the negative function of CD43 on T cell pro-
liferation is due entirely to an intracellular mechanism.
IL-2 Production Is Inhibited by the Presence of the CD43
ICD in the Immunological Synapse. The role of CD43 ex-
clusion in the regulation of proliferation has been tested by
Savage et al. (22). They found that expression of a mutant
CD43 construct in which the ERM-binding site was mu-
tated (CD43–NGG) reversed the hyperproliferation of the
CD43 /  T cells but did not decrease proliferation further
than transduction with the CD43FL construct. In light of
these findings, we have investigated whether the reversal
of the CD43 /  T cell hyperproliferation by the CD43–
NGG mutant was due to the presence of the CD43
ectodomain as suggested by the barrier hypothesis or the
ICD as suggested by our studies. When the CD43 intracel-
lular-only construct was also mutated at the ERM-binding
site (CD16-7–NGG), the CD16-7–NGG mutant reversed
the hyperproliferation of the CD43 /  T cells but did not
reduce proliferation further than that seen with CD16-7-
43–transduced T cells (Fig. 4 E). Thus, the negative effect
of CD43 on T cell proliferation is entirely due to the pres-
ence of its ICD, regardless of its location.
Our data on T cell proliferation suggest that the ec-
todomain is not involved in the regulatory function of
CD43. However, Delon et al. found that overexpression of
the CD43–NGG in WT T cells actually inhibited IL-2
production (15). The authors proposed that this was due to
the inability of these cells to move the large highly glyco-
sylated CD43 ectodomain from the T cell–APC contact
site. To address the apparent contradiction between our
data and those of Delon et al., we investigated the role of
CD43 exclusion on IL-2 production. First, we investigated
whether, similar to the data in Delon et al., transduction of
Figure 3. The presence of the CD43
ectodomain in the T cell–APC interaction
site is not sufficient to inhibit T cell pro-
liferation or activation. CD43 /  T cells
were transduced with either CD43FL or
CD43GPI and labeled with CFSE. Un-
sorted populations containing both trans-
duced and nontransduced cells were stim-
ulated with antigen-pulsed A20 cells.
The cells were analyzed for CD25 ex-
pression at 24 and 72 h for proliferation.
By flow cytometry, the CD4 CD43 
(transduced) cells were compared with
CD4 CD43  (nontransduced) cells from
the same culture. (A and B) Reintroduc-
tion of CD43FL into CD43 /  T cells
inhibited proliferation (A) and CD25
expression (B) to levels similar to CD43
WT T cells. (C and D) Reintroduction
of CD43GPI into CD43 /  T cells had
no effect on proliferation. The CD43-
transduced T cells proliferated as rapidly
as CD43 /  T cells at day 3 (C) and had
no decrease in CD25 expression (D).
*P   0.05; **P   0.01. Data are from
one representative experiment of a total
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the CD43–NGG mutant into CD43 /  T cells inhibited
IL-2 production. As seen in Fig. 4 C, upon restimulation
less IL-2 was produced by the CD43–NGG T cells than
the CD43FL T cells. However, CD43 /  T cells trans-
duced with CD16-7–NGG also produced significantly less
IL-2 upon restimulation than those transduced with move-
able CD16-7-43 (Fig. 4 D). Thus, our data does not sup-
port the interpretation of Delon and colleagues that CD43
regulation of IL-2 production is due to a steric interference
of T cell interactions by the CD43 ectodomain, since de-
creased IL-2 production required only the presence of the
CD43 ICD in the contact site. Further, our findings sug-
gest that although CD43 regulation of T cell proliferation
and IL-2 are both mediated through intracellular events,
moving the cytoplasmic region from the interaction site is
only required for some of its functions.
In conclusion, our study provides definitive evidence
against the barrier hypothesis for CD43 function. Our data
clearly demonstrate that the CD43 intracellular region is
necessary and sufficient for CD43 function, and we could
find no evidence for any effect of the extracellular region.
It remains to be determined how CD43 actually down-
regulates T cell activation. Previously, CD43 has been
shown to be phosphorylated on resting T cells, and this
phosphorylation increases upon T cell activation (23). We
propose that changes in CD43 phosphorylation may lead
to signaling events that regulate adhesion and activation.
Studies are underway in our laboratory to address this hy-
pothesis. Furthermore, the role of the CD43 ectodomain
remains to be explored. Several groups have identified po-
tential CD43 ligands (7, 24, 25), and engagement of these
CD43 ligands may provide positive costimulatory signals to
the T cell (11, 12). It is also possible that the CD43
ectodomain functions as a soluble molecule. In fact, soluble
CD43 ectodomain has been found at substantial levels in
human sera (26), and recent work has shown a novel role
for soluble CD43 in promoting stable interaction of myco-
bacteria with receptor on the macrophage, enabling the
cells to respond by producing TNF-  (27). Thus, further
studies are required to determine the distinct functions of
the extracellular, transmembrane, and cytoplasmic domains
of CD43.
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Figure 4. The cytoplasmic domain of CD43 is necessary and sufficient to inhibit T cell proliferation. (A and B) CD43 /  T cells were transduced with
the “inside only” construct CD16-7-43 or the control construct CD16-7. (A) The CD16-7-43–transduced T cells had significantly decreased T cell pro-
liferation compared with CD16-7–transduced control T cells. (B) CD25 expression at 24 h after stimulation with OVA peptide (0.3  g/ml)–pulsed A20
cells is decreased on CD16-7-43–transduced T cells. (C and D) CD43–NGG and CD16-7–NGG mutants decreased IL-2 production compared with
their WT controls. Sorted CD43FL and CD43–NGG T cells (C), CD16-7-43 and CD16-7–NGG (D) T cells were stimulated at 24 h with OVA peptide
(0.3  g/ml)–pulsed A20 cells. (E) CD43 /  T cells transduced with CD16-7-43 and CD16-7–NGG constructs were CFSE labeled, and proliferation
was measured at day 3. *P   0.05; **P   0.01. Data are from one representative experiment of a total of three independent experiments.Tong et al. Brief Definitive Report 1283
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